Clinical Trials
239 trialsSBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Fudan University
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
Peking Union Medical College Hospital
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
L-Nutra Inc
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Guangzhou University of Traditional Chinese Medicine
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
SNMM
Eye & ENT Hospital of Fudan University
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Shanghai Simnova Biotechnology Co.,Ltd.
LpDessai
Centre Hospitalier Universitaire de Besancon
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
SBRT/RT in Oligometastatic Stage IV NSCLC
University Hospital Ostrava
STARTNEWERA-OM
Radiotherapy Oncology Centre "Santa Maria" Hospital
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
DEBIRI
Fudan University
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
IMPROVE
Fudan University
PROACH
Ruijin Hospital
Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
Henan Cancer Hospital
DEDALUS
Fondazione IRCCS Policlinico San Matteo di Pavia
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
Henan Cancer Hospital
iCHRTL
Maria Sklodowska-Curie National Research Institute of Oncology
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
Double Filtration Plasmapheresis Combined With Chemotherapy
Zhongnan Hospital
HIST-RIC
Institut Paoli-Calmettes
SELENIUM
Seoul National University Hospital
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer
Universitätsklinikum Hamburg-Eppendorf
A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations
Tongji University
Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery
Yixing People's Hospital
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
Tianjin Medical University Cancer Institute and Hospital
NeoON
Institut fuer Frauengesundheit
An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC
Xijing Hospital
Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Shanghai Pulmonary Hospital, Shanghai, China
DC-CIK
Yantai Yuhuangding Hospital
NK
Yantai Yuhuangding Hospital
MILES-5
National Cancer Institute, Naples
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
COLT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
Shandong Cancer Hospital and Institute
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC(NICE-RT)
Shanghai Chest Hospital
A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer
Fujian Medical University
Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Shanghai Zhongshan Hospital
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
Henan Provincial People's Hospital
VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
Fudan University